Aduhelm: The New Alzheimer’s Drug and its Coverage Implications with Alzheimer’s Disease
by Giftina Wilson, PharmD Candidate On June 7, 2021, the FDA approved the controversial Aduhelm® (aducanumab) for treating Alzheimer’s Disease despite inadequate evidence of the drug’s efficacy based on a highly debated posthoc analysis.1 Currently, there is an ongoing discussion on whether Medicare will provide coverage of this new antibody to its beneficiaries. Aduhelm is […]